Following fields are empty!

1
Search
2
Select
3
Submit
225
Journals
Go to Previous Page
Page 4 of 12
Go to Next Page

Request Journal

Please fill in the form to request a new journal to be added. We will review your request and add it to the Journal Guide as soon as possible.

*

Current Neuropharmacology

ISSN: 1570-159X
SIGAPS Level B
Publisher: Bentham Science Publishers
Visit Publisher homepageVisit journal homepage
Medicine(all)Clinical NeurologyPharmacology (medical)Psychiatry and Mental healthUrologyNeurologyPharmacology

Current Neuropharmacology aims to provide current, timely and comprehensive reviews and guest edited issues of all areas of neuropharmacology and related matters of neuroscience. The reviews cover the fields of molecular, cellular, and systems/behavioural aspects of neuropharmacology and neuroscience.

Read more
Loading data ...
Compliant Options - Provided by Journal Checker Tool

Hybrid Journal

Go ahead and submit. Remember to select a CC BY licence to ensure compliance.

Transformative Agreement

Select the open access publishing option with a https://creativecommons.org/licenses/by/2.0/ license to ensure compliance.

Transformative Journal

Select the open access publishing option with a CC BY license to ensure compliance.

Full Open Access

Go ahead and submit. Remember to select a CC BY license to ensure compliance.

Self-Archiving

Following acceptance, please deposit your author accepted manuscript in a repository without embargo.

Self-Archiving using Rights Retention

Your funder’s grant conditions set out how you can retain sufficient rights to self-archive the Author Accepted Manuscript in any OA repository. Publishing fees do not apply with this route.

Unfortunately, this journal has no Plan-S compliant options - Provided by Journal Checker Tool

Go to Journal

Current Psychopharmacology

ISSN: 2211-5560eISSN: 2211-5579
Publisher: Bentham Science Publishers
Visit Publisher homepageVisit journal homepage
Pharmacology (medical)Psychiatry and Mental healthPharmacology

Current Psychopharmacology publishes peer-reviewed expert full-length/mini reviews, original research articles and single topic guest edited issues on all aspects of pre-clinical and clinical research in psychopharmacology. The journal aims to be the leading forum for expert review articles in the field. The journal also accepts high-level original research articles on outstanding topics of preclinical and clinical psychopharmacology.

Read more
Loading data ...
Compliant Options - Provided by Journal Checker Tool

Hybrid Journal

Go ahead and submit. Remember to select a CC BY licence to ensure compliance.

Transformative Agreement

Select the open access publishing option with a https://creativecommons.org/licenses/by/2.0/ license to ensure compliance.

Transformative Journal

Select the open access publishing option with a CC BY license to ensure compliance.

Full Open Access

Go ahead and submit. Remember to select a CC BY license to ensure compliance.

Self-Archiving

Following acceptance, please deposit your author accepted manuscript in a repository without embargo.

Self-Archiving using Rights Retention

Your funder’s grant conditions set out how you can retain sufficient rights to self-archive the Author Accepted Manuscript in any OA repository. Publishing fees do not apply with this route.

Unfortunately, this journal has no Plan-S compliant options - Provided by Journal Checker Tool

Go to Journal

Current Signal Transduction Therapy

ISSN: 1574-3624eISSN: 2212-389X
Publisher: Bentham Science Publishers
Visit Publisher homepageVisit journal homepage
EndocrinologyGeneticsPharmacology (medical)

The journal publishes timely in-depth reviews, research article and drug clinical trial studies in the field of signal transduction therapy. Thematic issues are also published to cover selected areas of signal transduction therapy. Coverage of the field includes genomics, proteomics, medicinal chemistry and the relevant diseases involved in signaling e.g. cancer, neurodegenerative and inflammatory diseases. Current Signal Transduction Therapy is an essential journal for all involved in drug design and discovery.

Read more
Loading data ...
Compliant Options - Provided by Journal Checker Tool

Hybrid Journal

Go ahead and submit. Remember to select a CC BY licence to ensure compliance.

Transformative Agreement

Select the open access publishing option with a https://creativecommons.org/licenses/by/2.0/ license to ensure compliance.

Transformative Journal

Select the open access publishing option with a CC BY license to ensure compliance.

Full Open Access

Go ahead and submit. Remember to select a CC BY license to ensure compliance.

Self-Archiving

Following acceptance, please deposit your author accepted manuscript in a repository without embargo.

Self-Archiving using Rights Retention

Your funder’s grant conditions set out how you can retain sufficient rights to self-archive the Author Accepted Manuscript in any OA repository. Publishing fees do not apply with this route.

Unfortunately, this journal has no Plan-S compliant options - Provided by Journal Checker Tool

Go to Journal

Current Therapeutic Research

ISSN: 0011-393XeISSN: 1879-0313
DOAJ Logo
SIGAPS Level D
Publisher: Elsevier
Visit Publisher homepageVisit journal homepage
Medicine(all)Pharmacology (medical)Pharmacology

Current Therapeutic Research serves an international audience of scientists and clinicians in a variety of research, academic and clinical practice settings by quickly disseminating research findings. The journal provides a home for the rapid publication ofOriginal reports of recent development in drug therapy, including papers presenting unexpected, controversial, provocative and/or negative resultsResearch letters, presenting research that may stimulate further investigation or alert readers to clinically relevant but preliminary findingsIn-depth review articles on specific drug therapies or disease statesApplied health economics papers, aimed at a clinical audienceTrials From Resource-Limited Settings intended to highlight original medical and pharmaceutical reports from resource-limited settings.CTR is a peer-reviewed, author pays, online journal and the final published article will be universally accessible on all of Elsevier's platforms. In addition, the articles are indexed by all major biomedical abstracting databases.Published articles range from studies exploring new drugs and new indications for existing drugs to large, multicenter Phase III and IV trials. The journal also encourages submission of brief reports and commentaries on topics that are timely or provocative. For further information click on the links belowOriginal ResearchReview Articles and Meta-analysesCommentariesBrief ReportsResearch LettersLetters to the Editor

Read more
Loading data ...
Compliant Options - Provided by Journal Checker Tool

Hybrid Journal

Go ahead and submit. Remember to select a CC BY licence to ensure compliance.

Transformative Agreement

Select the open access publishing option with a https://creativecommons.org/licenses/by/2.0/ license to ensure compliance.

Transformative Journal

Select the open access publishing option with a CC BY license to ensure compliance.

Full Open Access

Go ahead and submit. Remember to select a CC BY license to ensure compliance.

Self-Archiving

Following acceptance, please deposit your author accepted manuscript in a repository without embargo.

Self-Archiving using Rights Retention

Your funder’s grant conditions set out how you can retain sufficient rights to self-archive the Author Accepted Manuscript in any OA repository. Publishing fees do not apply with this route.

Unfortunately, this journal has no Plan-S compliant options - Provided by Journal Checker Tool

Institutional Agreement

Tous les auteurs correspondants des Hospices Civils de Lyon ont la possibilité de publier leurs articles de recherches en Open Access dans cette revue. Pour bénéficier de cette prise en charge, déclarez les "Hospices Civils de Lyon" dans votre affiliation principale et utilisez votre adresse mail "@chu-lyon.fr" lors de la soumission de votre article.

ATTENTION:

  • Si l'éditeur vous demande de sélectionner la licence applicable, privilégiez la licence CC-BY à toutes autres.
  • Pour les revues non éligibles, dont The Lancet et les revues Cell Press, ou en cas d’épuisement du stock de droits, la publication en accès ouvert immédiat devient payante mais de manière optionnelle ; le tarif bénéficie dans ce cas d’une remise de 10%.
  • Les articles publiés en accès ouvert immédiat au titre de l’accord peuvent être déposés dans leur version finale éditeur dans une archive ouverte, par exemple dans HAL-HCL.
  • Dans le cas des articles sous abonnement, il est permis par la Loi République numérique de déposer dans une archive ouverte le manuscrit auteur accepté d’un article et de le diffuser avec un embargo de 6 mois (sciences dures) ou 12 mois (SHS).

Si vous rencontrez des difficultés ou si vous avez des questions, contactez la Documentation Centrale sur sa.documentationcentrale@chu-lyon.fr ou au 04-72-11-29-99 (31-29-99)